NCT07248540 IV Magnesium in the Treatment of Acute Dysmenorrhea
| NCT ID | NCT07248540 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Havva Betül Bacak |
| Condition | Dysmenorrhea |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-07-01 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, randomized, double-blind clinical trial aims to evaluate the analgesic efficacy of intravenous magnesium sulfate in women presenting to the emergency department with acute dysmenorrhea. Participants will be randomized into two groups receiving either 2 ampoules of magnesium sulfate or intravenous dexketoprofen. Pain levels will be assessed using the Visual Analog Scale (VAS) before and after treatment.
Eligibility Criteria
Inclusion Criteria: Female patients aged 18 to 35 years Presenting to the obstetrics and gynecology emergency department with a diagnosis of primary dysmenorrhea Having regular menstrual cycles within the last 6 months Having a Visual Analog Scale (VAS) pain score of ≥6 at emergency admission Providing written informed consent for participation in the study Exclusion Criteria: Patients with secondary dysmenorrhea or underlying gynecological pathology Pregnancy or breastfeeding Use of analgesics or muscle relaxants within the last 3 days Known allergy to magnesium sulfate or dexketoprofen trometamol History of renal failure, cardiac arrhythmia, or serious systemic disease Inability to assess pain due to mental disability or communication disorder Failure to provide informed consent for participation in the study
Contact & Investigator
havva betül bacak, md
PRINCIPAL INVESTIGATOR
SBÜ Gaziosmanpaşa Training and Research Hospital
Frequently Asked Questions
Who can join the NCT07248540 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 35 Years, studying Dysmenorrhea. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07248540 currently recruiting?
Yes, NCT07248540 is actively recruiting participants. Contact the research team at ecenurcelikoglu14@gmail.com for enrollment information.
Where is the NCT07248540 trial being conducted?
This trial is being conducted at Gaziosmanpaşa, Turkey (Türkiye).
Who is sponsoring the NCT07248540 clinical trial?
NCT07248540 is sponsored by Havva Betül Bacak. The principal investigator is havva betül bacak, md at SBÜ Gaziosmanpaşa Training and Research Hospital. The trial plans to enroll 60 participants.